Disease Diagnosis TRIZ Cases
- Red Blood Cell ROS Measurement With Hydroxylamine EPR Probes
Hydroxylamine probes convert RBC superoxide into stable nitroxides for EPR measurement, addressing weak storage-quality assessment.
- Anticoagulant Therapeutic Efficacy Assay With Fluorogenic Thrombin Detection
Fluorogenic AMC and V-P-R-AMC substrates detect thrombin generation as low as 5 pM to assess anticoagulant efficacy.
- Newborn Screening Using Immuno-SRM for Low-Abundance Disease Peptides
High-affinity antibodies enrich low-abundance peptides from dried blood spots, enabling multiplexed immuno-SRM screening before symptoms appear.
- Calpain-Cleaved SNTF Blood Biomarker for Persistent Cognitive Dysfunction
SNTF links acute axonal damage with white matter risk and persistent cognitive dysfunction in CT-negative mTBI patients.
- Condensate Screening for Selective Macromolecule Association
Selective association screening separates macromolecule effects from whole-condensate disruption, supporting tissue-specific compound discovery.
- CTC Drug Sensitivity Assays for Cancer Therapy Response Prediction
Parallel assays test immunotherapeutic and chemotherapeutic agents on CTCs and biopsy-derived cells to predict response in 10 days.
- T Cell Biomarker Kits for Predicting Autoimmune Disease Flare
CD3+CD4+ T-cell biomarker ratios help predict autoimmune disease flare before biologic DMARD withdrawal, limiting unnecessary exposure.
- PTX3 Biomarker Detection for Faster Neonatal Sepsis Diagnosis
Measuring PTX3 before blood-culture results helps identify late-onset neonatal sepsis and reduce unnecessary antibiotic exposure.
- Blood-Based Alzheimer's Diagnosis with Anti-YB-1 Autoantibody Detection
Learn how blood immunoassays measure anti-YB-1 autoantibodies to support non-invasive Alzheimer's disease diagnosis.
- HFpEF Treatment Through Biomarker-Guided NO-cGMP-PKG Stratification
Biomarkers such as Nox5 and nitrotyrosine identify HFpEF endotypes before targeted NO-cGMP-PKG therapy.
- Exopher Detection and Cargo Analysis for Kidney Disease Monitoring
Urine exopher analysis reveals podocyte-derived proteostatic dysfunction markers for non-invasive kidney disease diagnosis and monitoring.
- Quantitative Serum DEFA Detection Kit for Rapid Cancer Screening
The kit quantifies reduced DEFA in serum with ELISA or LFA, avoiding complex separation for rapid multi-cancer screening.
- Soluble Protein Signatures for Personalized Pancreatic Cancer Treatment
When PDAC diagnosis and prognosis are unreliable, soluble immune protein signatures help guide surgery or alternative treatment decisions.
- Cyclohexane Carboxylic Acid Biomarkers for IBS Dietary Response
Stool testing measures cyclohexane carboxylic acid compounds by GC-MS to estimate IBS probability and predict dietary response.
- Autoantibody Biomarker Panels for Anti-Ro-Negative Sjögren’s Diagnosis
Specific autoantibody panels identify anti-Ro-negative Sjögren’s syndrome from liquid samples without salivary gland biopsy.
- PCT and proADM Biomarker Monitoring for Sepsis Antibiotic Guidance
Compare PCT and proADM levels before and after antibiotics to guide treatment changes and identify high-risk patients early.
- Two-Sample UCH-L1 and GFAP Testing for Hyperacute TBI Diagnosis
Two blood samples collected after head injury track UCH-L1 and GFAP changes for objective TBI severity assessment beyond CT.
- Single-Molecule Cardiac Troponin Detection for Earlier ACS Diagnosis
Conventional CK-MB assays can delay cardiac damage detection; fluorescent single-molecule cTnI analysis supports detection within 3–4 hours.
- Peanut Antigen Composition Profiling With LC-MS/MS Release Analysis
Enzymatic digestion and LC-MS-MS quantify peptide fragments to reveal low-level peanut allergen signatures and release profiles.
- Single-Cell FRET Biosensors for Metastatic Potential and Chemoresistance
Dynamic FRET signals distinguish metastatic potential and chemoresistance in living single cancer cells despite tumor heterogeneity.
- F. prausnitzii-Specific DP8a Cell Detection for Noninvasive IBD Assessment
CCR6 and CXCR6 markers identify F. prausnitzii-specific DP8a cells in blood, supporting non-invasive IBD diagnosis, prognosis, and treatment monitoring.
- proADM Measurement in Patient Samples for Platelet Risk Stratification
Measure proADM in patient samples to improve platelet abnormality risk stratification and flag possible DIC or organ failure.